Scientist profiles G-L
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room FG 19
Administrative Assistant: Kathy Ostaff
- MD, 1983, University of Toronto, Canada
- FRCP(C), 1988, psychiatry, U of T, Canada
Appointments and Affiliations:
- Associate scientist, Evaluative Clinical Sciences, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute
- Richard Lewar Chair in Geriatric Psychiatry, Sunnybrook Health Sciences Centre and U of T
- Head, division of geriatric psychiatry, Sunnybrook Health Sciences Centre
- Head, division of geriatric psychiatry, department of psychiatry, U of T (1995–2005)
- Professor, department of psychiatry, faculty of medicine, U of T
- Clinical neuropharmacology
- Geriatric psychiatry
Dr. Herrmann's major contributions to neuroscience research are in the areas of the clinical pharmacology of dementia (treatment of behavioural disturbances and cognition), post-stroke depression and the pharmacotherapy of late-life affective disorders. He has published numerous studies on the pharmacotherapy of behavioural disturbances in dementia that involve the use of novel agents, which attempt to determine the underlying neurobiology of these disorders. He has also participated in studies of post-stroke depression examining its neuroimaging and biological correlates. In addition, he has published studies, reviews and guidelines on the management of depression and bipolar illness in late-life, and has participated in psychopharmacology projects on drug-drug interactions and adverse events.
- Herrmann N, O’Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, Lanctôt KL. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in moderate to severe Alzheimer’s disease patients. J Am Med Dir Assoc. 2016 Feb;17:142–7.
- Herrmann N, Harimoto T, Balshaw R, Lanctôt KL. The Canadian outcomes study of dementia (COSID) investigators: Risk factors for progression of Alzheimer’s disease in a Canadian population: The Canadian outcomes study in dementia (COSID). Can J Psychiatry. 2015 Apr;60(4):189–199.
- Herrmann N, Hogan D, Lanctôt KL. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the diagnosis and treatment of dementia 2012. Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S5.
- Herrmann N, Gauthier S, Boneva N, Lemming OM. A randomized, double-blind placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. Int Psychogeriatr. 2013 Jun;25(6):919–27.
Related News and Stories:
- Dementia and driving: when it’s time to hang up the keys (Huffington Post, July 12, 2016)
- When to call it quits: Study examines health effects of stopping drug treatments in elderly patients with Alzheimer’s disease (Jan. 29, 2016)
- Take three sardines and call me in the morning: Could fish oil help treat cognitive impairment? (from 2013 SRI Magazine)
- Symptoms of Alzheimer's significantly improved with new treatment (The Globe and Mail, April 2, 2013)
- Sunnybrook researchers studying emotional issues in Alzheimer's patients (The Globe and Mail, Jan. 13, 2012)
- Boom, baby boom!: Aging, dementia and the cost to family caregivers (from 2011 SRI Magazine)
- When should doctors take the keys from older drivers? (The Toronto Star, March 20, 2010)
- Severe Alzheimer's management recommendations: Condition requires more frequent monitoring by health professionals, says new report (Dec. 1, 2008)
- Dementia patients on psychotropic medications at high risk for collisions: Symptoms or prescription of meds should prompt physicians to evaluate effect on road safety (Oct. 8, 2008)
- Caring enough: Two SRI neuroscientists investigate the link between Alzheimer’s disease and apathy (Feb. 19, 2008)
- The skeptics: Two SRI docs question new findings on a drug: A feature from Research Report 2004-2006